Test Directory
Hexagonal Phospholipid aPTT
Justification
The presence of antiphospholipid antibodies, such as lupus anticoagulant, increases the risk of arterial thrombosis, venous thrombosis, thrombocytopenia and recurrent miscarriage. Lupus anticoagulants result in the prolongation of clotting times which correct with the addition of phospholipids.
STAT: < 48 hours (M-F)
Clot-based
Draw Tube: Blue Top
Sample Type: Citrated Plasma
Specimen Requirements
Sample Type | Volume Required | Minimum Volume | Stability | |
---|---|---|---|---|
PREFERRED | Citrated Plasma | 1mL | 0.5mL | Frozen (-20C): 2 weeks Frozen (-80C): 6 months |
ALTERNATIVE | - | - | - | - |
REJECTION CRITERIA | Thawed in transit, refrozen or clotted sample |
SPECIAL INSTRUCTIONS | - |
General Information
METHODOLOGY | Clot-based |
STAT TAT | < 48 hours (M-F) |
STAT TAT Performance | > 90% of results released in 48 hours |
ROUTINE TAT | < 1 week |
ALTERNATIVE NAMES | Hex Phos |
DESCRIPTION | Hexagonal phase phospholipid (HPP) neutralization assay. Addition of HPPs neutralize the effect of lupus anticoagulant antibodies present and results in correction of the prolonged aPTT. |
LIMITATIONS | - |
NORMAL RANGE | Ratio < 11 |
ASSOCIATED TESTING | - |
REFERENCES | - |
SAMPLE REPORT | Upon request |
NEW YORK STATE APPROVED | - |
Test Codes
ORDER CODE | P3303 |
CPT CODE | 85730x2 |
LOINC CODE | 3282-1 |